Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC

Objective To study the relationship between seven antibody of lung cancer and the chemotherapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). Methods A total of 42 patients with NSCLC admitted to Taihe County People's Hospital from June 2022 to December 2023 were selected. All subjects underwent 4 cycles of chemotherapy. They were divided into effective group (n=25) and non-effective group (n=17) according to the outcome of chemotherapy. The seven antibody of lung cancer were titrated and compared and the efficacy in evaluating chemotherapy was analyzed by receiver operating characteristic (ROC) curve. In addition, the subjects were divided into a good prognosis group (n=21) and a poor prognosis group (n=21) according to the difference in clinical outcomes. The seven antibody of lung cancer were titrated and compared between the two groups, and the relationship between the antibody level and the prognosis of NSCLC patients was determined by multivariate Logistic regression analysis. Results The antibody level in effective group was lower than that in the non-effective group (P＜0.05). ROC curve analysis confirmed that the level of CAGE,GAGE7, GBU4-5, P53,PGP95, SOX2 and MAGEA1 is significantly related to better efficacy of chemotherapy and the areas under the curve were 0.861, 0.769, 0.778, 0.786, 0.793, 0.842 and 0.833, respectively. The antibody level of lung cancer in poor prognosis group was higher than those in good prognosis group (P＜0.05). Multiple Logistic regression analysis confirmed that the seven antibody levels were the risk factors for poor prognosis in NSCLC patients(all OR value＞1, P＜0.05). Conclusions The level of seven antibody of lung cancer are negatively related to the chemotherapy effect and prognosis of NSCLC patients. With increase of the seven antibody level of lung cancer, prognosis of patients resulted from chemotherapy is worse.